A biofunctional assay to study pRL-CMV plasmid DNA formulation stability

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmaceutical Sciences

Background:

• Plasmid DNA stability is crucial for pharmaceutical formulations.
• Current methods for assessing DNA stability, like agarose gel electrophoresis, may lack sensitivity.
• Accurate assessment of plasmid DNA integrity is needed to ensure therapeutic efficacy.

Purpose of the Study:

• To develop and validate a sensitive cotransfection method for assessing plasmid DNA stability.
• To evaluate the impact of buffer composition on plasmid DNA degradation.
• To establish a predictive tool for the stability of plasmid DNA dosage forms.

Main Methods:

• A cotransfection assay was employed to measure the functional protein-coding ability of plasmid DNA as a marker for stability.
• DNA degradation rates were measured to validate the cotransfection method.
• The method was compared against standard agarose gel electrophoresis for quantifying DNA damage.

Main Results:

• The cotransfection method demonstrated higher sensitivity and reproducibility compared to single plasmid transfection.
• Buffer choice, specifically citrate buffer concentration, was found to influence DNA degradation rates.
• The cotransfection assay effectively quantified subtle damage to pRL-CMV plasmid DNA, outperforming agarose gel electrophoresis.

Conclusions:

• The developed cotransfection method is a superior tool for assessing plasmid DNA stability and integrity.
• Buffer composition plays a significant role in the pharmaceutical formulation of plasmid DNA.
• This method can aid in predicting the stability of final plasmid DNA dosage forms, ensuring product quality and efficacy.